藥明巨諾-B(02126.HK)與2seventy bio訂立合作協議
格隆匯10月27日丨藥明巨諾-B(02126.HK)發佈公吿,公司已與2seventy bio於2022年10月27日訂立合作協議,據此,公司與2seventy bio有條件同意建立戰略聯盟,在大中華開發及商業化用於腫瘤適應症的針對MAGE-A4(包括與MAGE-A4結合的工程TCR的任何突變、片段、變型或衍生物)的細胞治療產品,且有可能擴大合作,納入其他項目及其他產品。
根據合作協議: (1)2seventy bio有條件授予公司及其聯屬公司由2seventy bio控制的若干專利及專有技術的權利和許可,以便公司及其聯屬公司在大中華開發、生產及商業化產品; (2)公司有條件同意向2seventy bio支付預付款及若干里程碑付款及支付特許權使用費;及公司將全權負責並承擔在大中華開發及商業化而生產及供應產品的所有成本及開支。
根據披露,2seventy bio是一家從事癌症革新療法的研究、開發及商業化的細胞及基因療法公司,旨在真正顛覆癌症治療領域。其方法結合其在T細胞工程技術及慢病毒載體基因傳遞方法的專業知識、細胞療法的研究、開發及生產的經驗以及能夠選擇性部署以開發用於癌症患者的高度創新的下一代靶向細胞療法的一套技術。 2seventy bio的領先產品ABECMA為獲得美國食品藥物管理局批准用於治療多發性骨髓瘤的首個CAR T細胞療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.